These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma. Ma Y; Hou Y; Liu B; Li X; Yang S; Ma J Anat Rec (Hoboken); 2010 Nov; 293(11):1847-54. PubMed ID: 20730866 [TBL] [Abstract][Full Text] [Related]
23. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors. Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328 [TBL] [Abstract][Full Text] [Related]
24. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748 [TBL] [Abstract][Full Text] [Related]
25. High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas. Ramani P; Sowa-Avugrah E; May MT Virchows Arch; 2015 Sep; 467(3):319-27. PubMed ID: 26199132 [TBL] [Abstract][Full Text] [Related]
26. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas. Dungwa JV; Hunt LP; Ramani P Hum Pathol; 2012 Oct; 43(10):1651-60. PubMed ID: 22436629 [TBL] [Abstract][Full Text] [Related]
27. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121 [TBL] [Abstract][Full Text] [Related]
28. Intratumoral but not peritumoral lymphatic vessel density measured by D2-40 expression predicts poor outcome in gastric cancer--ROC curve analysis to find cut-off point. Donizy P; Rudno-Rudzinska J; Halon A; Dziegala M; Kabarowski J; Frejlich E; Dziegiel P; Kielan W; Matkowski R Anticancer Res; 2014 Jun; 34(6):3113-8. PubMed ID: 24922680 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664 [TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590 [TBL] [Abstract][Full Text] [Related]
31. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma. Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154 [TBL] [Abstract][Full Text] [Related]
33. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300 [TBL] [Abstract][Full Text] [Related]
34. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology. Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077 [TBL] [Abstract][Full Text] [Related]
35. Clinical significance of NTRK family gene expression in neuroblastomas. Light JE; Koyama H; Minturn JE; Ho R; Simpson AM; Iyer R; Mangino JL; Kolla V; London WB; Brodeur GM Pediatr Blood Cancer; 2012 Aug; 59(2):226-32. PubMed ID: 21990266 [TBL] [Abstract][Full Text] [Related]
36. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas. de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235 [TBL] [Abstract][Full Text] [Related]
37. [Clinicopathologic features of peripheral neuroblastic tumors]. Yang BF; Fu LB; He LJ Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586 [TBL] [Abstract][Full Text] [Related]
38. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity. Ozer E; Altungoz O; Unlu M; Aygun N; Tumer S; Olgun N Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):181-6. PubMed ID: 17525631 [TBL] [Abstract][Full Text] [Related]
39. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600 [TBL] [Abstract][Full Text] [Related]
40. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]